GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Cyclically Adjusted PS Ratio

BIOYF (Biosyent) Cyclically Adjusted PS Ratio : 5.71 (As of Jun. 01, 2025)


View and export this data going back to . Start your Free Trial

What is Biosyent Cyclically Adjusted PS Ratio?

As of today (2025-06-01), Biosyent's current share price is $8.6174. Biosyent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $1.51. Biosyent's Cyclically Adjusted PS Ratio for today is 5.71.

The historical rank and industry rank for Biosyent's Cyclically Adjusted PS Ratio or its related term are showing as below:

BIOYF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.77   Med: 6.73   Max: 28.31
Current: 5.43

During the past years, Biosyent's highest Cyclically Adjusted PS Ratio was 28.31. The lowest was 3.77. And the median was 6.73.

BIOYF's Cyclically Adjusted PS Ratio is ranked worse than
80.49% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs BIOYF: 5.43

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biosyent's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.664. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.51 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biosyent Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biosyent's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Cyclically Adjusted PS Ratio Chart

Biosyent Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.24 6.14 4.35 4.97 5.29

Biosyent Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.54 5.04 5.28 5.29 5.13

Competitive Comparison of Biosyent's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Cyclically Adjusted PS Ratio falls into.


;
;

Biosyent Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biosyent's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=8.6174/1.51
=5.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Biosyent's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.664/129.1809*129.1809
=0.664

Current CPI (Mar. 2025) = 129.1809.

Biosyent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.201 100.500 0.258
201509 0.242 100.421 0.311
201512 0.195 99.947 0.252
201603 0.197 101.054 0.252
201606 0.233 102.002 0.295
201609 0.250 101.765 0.317
201612 0.246 101.449 0.313
201703 0.197 102.634 0.248
201706 0.292 103.029 0.366
201709 0.303 103.345 0.379
201712 0.312 103.345 0.390
201803 0.236 105.004 0.290
201806 0.309 105.557 0.378
201809 0.277 105.636 0.339
201812 0.303 105.399 0.371
201903 0.233 106.979 0.281
201906 0.276 107.690 0.331
201909 0.341 107.611 0.409
201912 0.311 107.769 0.373
202003 0.320 107.927 0.383
202006 0.270 108.401 0.322
202009 0.337 108.164 0.402
202012 0.348 108.559 0.414
202103 0.457 110.298 0.535
202106 0.462 111.720 0.534
202109 0.411 112.905 0.470
202112 0.443 113.774 0.503
202203 0.439 117.646 0.482
202206 0.410 120.806 0.438
202209 0.408 120.648 0.437
202212 0.445 120.964 0.475
202303 0.384 122.702 0.404
202306 0.488 124.203 0.508
202309 0.544 125.230 0.561
202312 0.514 125.072 0.531
202403 0.481 126.258 0.492
202406 0.553 127.522 0.560
202409 0.597 127.285 0.606
202412 0.527 127.364 0.535
202503 0.664 129.181 0.664

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biosyent  (OTCPK:BIOYF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biosyent Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biosyent's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Biosyent Headlines

From GuruFocus

BioSyent Declares Second Quarter 2025 Dividend

By GlobeNewswire 05-15-2025

Q2 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

BioSyent to Attend Planet MicroCap Showcase

By GlobeNewswire 04-14-2025

Q3 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2022 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2018 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024